In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a price target of $20.00.
Tyler Van Buren’s rating is based on several compelling factors that highlight Arcutis Biotherapeutics’ strong market position and growth potential. The company demonstrated impressive commercial execution with its Zoryve product, achieving $69 million in Q4 sales, which exceeded expectations by approximately 26%. This robust performance is expected to continue into 2025, supported by the anticipated approval for scalp and body psoriasis treatment, which should further enhance revenue streams.
Additionally, Arcutis Biotherapeutics is well-positioned in the market with its leadership in the branded anti-inflammatory topical class, catering to a significant patient population. The company’s strategic initiatives, including product label expansion and partnerships, notably with Odell Beckham Jr., are poised to increase patient awareness and drive further growth. The shift away from topical steroids presents a substantial opportunity for Zoryve, and the company’s pricing and access strategies have already shown success in improving reimbursement. Furthermore, near-term intellectual property litigation is not expected to pose a significant risk, reinforcing the positive outlook for the stock.
Questions or Comments about the article? Write to editor@tipranks.com